| Field | Specification |
|---|---|
| Target | |
| Alternative names | Prolyl endopeptidase FAP ;3.4.21.26 ;170 kDa melanoma membrane-bound gelatinase ;Dipeptidyl peptidase FAP ;3.4.14.5 ;Fibroblast activation protein alpha ;FAPalpha ;Gelatine degradation protease FAP ;3.4.21.- ;Integral membrane serine protease ;Post-proline cleaving enzyme ;Serine integral membrane protease ;SIMP ;Surface-expressed protease ;Seprase ;Antiplasmin-cleaving enzyme FAP, soluble form ;APCE ;3.4.14.5 ;3.4.21.- ;3.4.21.26 ;FAP ; |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human FAP1 |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone AbF22 is a rabbit monoclonal antibody that recognizes prolyl endopeptidase FAP in human, mouse and rat samples and is validated for Western blot and IHC. The predicted molecular weight is 87.7 kDa, and the supplier reports an observed band at about 95 kDa.
Fibroblast activation protein (FAP) is a cell surface serine protease that cuts peptide bonds after proline residues and can also break down gelatin and denatured collagen. It is found mainly on activated fibroblasts, such as those in healing wounds, fibrotic tissue and the stroma of many tumors, which makes it a common marker in studies of tissue remodeling and cancer-associated fibroblasts.
| Target | Prolyl endopeptidase FAP (gene FAP; UniProt Q12884, human) |
|---|---|
| Clone | AbF22 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Calculated MW | 87.7 kDa |
| Observed MW | 95 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:500–1:2000 |
|---|---|
| Immunohistochemistry | 1:50–1:200 |
Samples with a confirmed band (WB): human U-87MG cells, rat skin tissue, mouse skin tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1:1, HRP-conjugated secondary antibody at 1:500, ECL detection.
Samples with confirmed staining (IHC): human breast cancer tissue, human colon cancer tissue, human esophageal squamous cells carcinoma tissue, human lung cancer tissue, human liver cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Synthetic peptide based on the sequence of human FAP1.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places prolyl endopeptidase FAP in the [Prolyl endopeptidase FAP]: Cell surface, cell membrane, cell projection and membrane. Tissue expression noted by UniProt (human): Expressed in adipose tissue. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Wei Chuanyuan et al. (2023) Delineating the early dissemination mechanisms of acral melanoma by integrating single-cell and spatial transcriptomic analyses. Nature Communications. 10.1038/s41467-023-43980-y
Fei Long et al. (2024) DAB2+ macrophages support FAP+ fibroblasts in shaping tumor barrier and inducing poor clinical outcomes in liver cancer. Theranostics. 10.7150/thno.99046
Cai Zhimou et al. (2023) Single-cell RNA sequencing reveals pro-invasive cancer-associated fibroblasts in hypopharyngeal squamous cell carcinoma. Cell Communication and Signaling. 10.1186/s12964-023-01312-z
Zhaoxuan Wang et al. (2025) Case Report: FAP+ fibroblasts and SPP1+ macrophages in SMARCA2-deficient while SMARCA4-preserved poorly differentiated lung adenocarcinoma: two case reports and multi-omics analysis. Frontiers in Immunology. 10.3389/fimmu.2025.1568556
Zhang Yafei et al. (2025) Characteristics of 18F-FAPI-04 PET/CT in patients with peritoneal metastasis and to predict treatment efficacy, a head-to-head comparison with 18F-FDG PET/CT. Cancer Imaging. 10.1186/s40644-025-00887-9
Baojia Zou et al. (2018) The Expression of FAP in Hepatocellular Carcinoma Cells is Induced by Hypoxia and Correlates with Poor Clinical Outcomes. Journal of Cancer. 10.7150/jca.25775
Geyang Dai et al. (2023) Small Leucine-Rich Proteoglycan PODNL1 Identified as a Potential Tumor Matrix-Mediated Biomarker for Prognosis and Immunotherapy in a Pan-Cancer Setting. Current Issues in Molecular Biology. 10.3390/cimb45070386
Bin Ma et al. (2023) Down-regulation of COL1A1 inhibits tumor-associated fibroblast activation and mediates matrix remodeling in the tumor microenvironment of breast cancer. Open Life Sciences. 10.1515/biol-2022-0776
